Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Apr 18, 2023
Date Accepted: Nov 22, 2023

The final, peer-reviewed published version of this preprint can be found here:

Involving Patients and Clinicians in the Design of Wireframes for Cancer Medicines Electronic Patient Reported Outcome Measures in Clinical Care: Mixed Methods Study

Dunlop E, Ferguson A, Mueller T, Baillie K, Laskey J, Clarke J, Kurdi A, Wales A, Connolly T, Bennie M

Involving Patients and Clinicians in the Design of Wireframes for Cancer Medicines Electronic Patient Reported Outcome Measures in Clinical Care: Mixed Methods Study

JMIR Form Res 2023;7:e48296

DOI: 10.2196/48296

PMID: 38127422

PMCID: 10767627

Involving patients and clinicians in the design of wireframes for cancer medicines electronic patient reported outcome measures (ePROMs) in clinical care: a mixed methods study

  • Emma Dunlop; 
  • Aimee Ferguson; 
  • Tanja Mueller; 
  • Kelly Baillie; 
  • Jennifer Laskey; 
  • Julie Clarke; 
  • Amanj Kurdi; 
  • Ann Wales; 
  • Thomas Connolly; 
  • Marion Bennie

ABSTRACT

Background:

The cancer medicines landscape is rapidly evolving. Electronic Patient Reported Outcome Measures (ePROMs) can help identify patients’ supportive care needs relating to treatment.

Objective:

This study aims to establish what could constitute a useful and easy to use patient app and clinician dashboard for cancer medicines ePROMs in routine cancer care, and understand intention to use these technologies.

Methods:

A two stage, mixed methods approach was adopted: interviews and focus groups with cancer clinicians and patients to test wireframes (i.e. mock-ups) of a clinician dashboard and a patient app for face validity (Stage 1); and based on refinements, validate the improved wireframes through online questionnaires (Stage 2).

Results:

14 clinicians and 19 patients participated in Stage 1 interviews/focus groups. All agreed the app/dashboard looked easy to use and that they would intend to use it (if available). Clinicians had concerns around integrating the dashboard into existing care records. In Stage 2, eight clinicians and 16 patients completed online questionnaires. All reported a relatively high perceived ease of use, usefulness and intention to use each technology. Although clinicians felt viewing patient reported outcome measures (PROMs) via the dashboard would have little influence on their treatment decision making, they would still use the dashboard.

Conclusions:

This study explores the perceived ease of use, usefulness and intention to use ePROMs solutions in cancer services in Scotland. Patients and clinicians stated they would find such technologies easy to use, useful and would intend to use them routinely if available. Some differences were identified between the two stages, which warrant further research.


 Citation

Please cite as:

Dunlop E, Ferguson A, Mueller T, Baillie K, Laskey J, Clarke J, Kurdi A, Wales A, Connolly T, Bennie M

Involving Patients and Clinicians in the Design of Wireframes for Cancer Medicines Electronic Patient Reported Outcome Measures in Clinical Care: Mixed Methods Study

JMIR Form Res 2023;7:e48296

DOI: 10.2196/48296

PMID: 38127422

PMCID: 10767627

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.